伏诺拉生治疗酸相关性疾病的研究进展  

Research progress of vonoprazan in treatment of acid-related diseases

作　　者：李卉[1] 张宏亮[1] 黄振光[1] LI Hui;ZHANG Hong-liang;HUANG Zhen-guang(Department of Pharmacy,the First Afiliated Hospital of Guangxi Medical University,Nanning GUANGXI 530021,China)

机构地区：[1]广西医科大学第一附属医院药学部,广西南宁530021

出　　处：《中国新药与临床杂志》2022年第8期459-465,共7页Chinese Journal of New Drugs and Clinical Remedies

基　　金：广西自然科学基金(2017GXNSFBA198177);广西壮族自治区卫生和计划生育委员会自筹经费科研项目(Z20180958)。

摘　　要：伏诺拉生为钾离子竞争性酸阻断剂,是一种新型抑酸药物,可以竞争性地阻断胃H^(+)/K^(+)-ATP酶的钾离子结合位点进而产生抑制胃酸分泌的作用。伏诺拉生于2019年12月在中国获批上市,用于治疗反流性食管炎,目前已成为酸相关性疾病治疗领域的研究热点。大量临床研究证实,相较于其他抑酸药物,伏诺拉生在治疗胃食管反流病、幽门螺杆菌感染、内镜下黏膜下剥离术后人工溃疡和迟发性出血以及消化性溃疡方面具有起效快、抑酸作用更强和更持久、安全性良好的优点。Vonoprazan is a potassium competitive acid blocker.As a novel acid inhibitor,vonoprazan plays a role in inhibiting gastric acid secretion by competitively blocking the potassium-binding site of the gastric H^(+)/K^(+)-ATPase.Vonoprazan was approved in China for the treatment of reflux esophagitis in December,2019.At present,it has become a research hotspot in the field of acid-related diseases treatment.Compared with other acid inhibitors,vonoprazan has the advantages of rapid effect,high efficiency,and good safety in the treatment of gastroesophageal reflux disease,Helicobacter pylori infection,artificial ulcer and delayed hemorrhage after endoscopic submucosal dissection and peptic ulcer,which has been verified in many clinical trials.

关 键 词：伏诺拉生 食管炎 消化性 临床研究 

分 类 号：R975.2[医药卫生—药品]